Citius Retained Earnings from 2010 to 2024
| CTOR Stock | 0.94 0.06 6.00% |
Retained Earnings | First Reported 2010-12-31 | Previous Quarter -16.3 M | Current Value -17.1 M | Quarterly Volatility 4.9 M |
Check Citius Oncology, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Citius Oncology,'s main balance sheet or income statement drivers, such as Tax Provision of 460.8 K, Selling General Administrative of 5.1 M or Total Revenue of 0.0, as well as many indicators such as . Citius financial statements analysis is a perfect complement when working with Citius Oncology, Valuation or Volatility modules.
Citius |
Latest Citius Oncology,'s Retained Earnings Growth Pattern
Below is the plot of the Retained Earnings of Citius Oncology, over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Citius Oncology,'s Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Citius Oncology,'s overall financial position and show how it may be relating to other accounts over time.
| Retained Earnings | 10 Years Trend |
|
Retained Earnings |
| Timeline |
Citius Retained Earnings Regression Statistics
| Arithmetic Mean | (7,784,706) | |
| Coefficient Of Variation | (62.71) | |
| Mean Deviation | 3,763,370 | |
| Median | (5,432,599) | |
| Standard Deviation | 4,881,402 | |
| Sample Variance | 23.8T | |
| Range | 12.7M | |
| R-Value | (0.69) | |
| Mean Square Error | 13.5T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (752,473) | |
| Total Sum of Squares | 333.6T |
Citius Retained Earnings History
About Citius Oncology, Financial Statements
Citius Oncology, shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Citius Oncology, investors may analyze each financial statement separately, they are all interrelated. The changes in Citius Oncology,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Citius Oncology,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -16.3 M | -17.1 M |
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.8 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.72 | ESPR | Esperion Therapeutics | PairCorr |
| 0.7 | GILD | Gilead Sciences | PairCorr |
| 0.67 | FLGC | Flora Growth Corp | PairCorr |
| 0.6 | NBY | NovaBay Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.